Journal of Viral Hepatitis

The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium
pp. 399-408(10)
Authors: Matheï, C.; Van Dooren, S.; Lemey, P.; Van Damme, P.; Buntinx, F.; Vandamme, A.-M.

HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance
pp. 409-420(12)
Authors: Ruys, T. A.; Nanlohy, N. M.; van den Berg, C. H. S. B.; Hassink, E.; Beld, M.; van de Laar, T.; Bruisten, S.; Wit, F.; Krol, A.; Prins, M.; Lange, J.; van Baarle, D.

Hepatitis C in ethnic minority populations in England
pp. 421-426(6)
Authors: Mann, A. G.; Trotter, C. L.; Adekoyejo Balogun, M.; Ramsay, M. E.

Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy
pp. 427-433(7)
Authors: de Lédinghen, V.; Barreiro, P.; Foucher, J.; Labarga, P.; Castéra, L.; Vispo, M. E.; Bernard, P.-H.; Martin-Carbonero, L.; Neau, D.; García-Gascó, P.; Merrouche, W.; Soriano, V.

Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection
pp. 434-441(8)
Authors: Papatheodoridis, G. V.; Chrysanthos, N.; Hadziyannis, E.; Cholongitas, E.; Manesis, E. K.

In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B
pp. 442-448(7)
Authors: Loggi, E.; Gramenzi, A.; Margotti, M.; Cursaro, C.; Galli, S.; Vitale, G.; Grandini, E.; Scuteri, A.; Vukotic, R.; Andreone, P.; Bernardi, M.

A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China
pp. 449-458(10)
Authors: Zhu, L.; Tse, C. -H.; Wong, V. W. -S.; Chim, A. M. -L.; Leung, K. -S.; Chan, H. L. -Y.

Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity
pp. 459-470(12)
Authors: Yu, H.; Babiuk, L. A.; van Drunen Littel-van den Hurk, S.

Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?
pp. 471-471(1)
Authors: Aghemo, Alessio; Rumi, Maria Grazia; Colombo, Massimo

FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence
pp. 472-473(2)
Authors: Poynard, T.; Munteanu, M.; Ngo, Y.; Moussalli, J.; Lebray, P.; Thabut, D.; Benhamou, Y.; Ratziu, V.

Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases
pp. 474-474(1)
Authors: Sebastiani, G.; Vario, A.; Guido, M.; Alberti, A.